Page 1

Rowsley Ltd's Skies VB Sdn Bhd receives approval from PTG to sell property units in SKIES-Vantage Bay to foreigners

Wednesday, 6 Aug 2014 06:09am EDT

Rowsley Ltd:Says Skies VB Sdn Bhd, wholly-owned subsidiary of the Company, has received approval from Pejabat Pengarah Tanah Dan Galian Johor (PTG) to sell property units in SKIES-Vantage Bay to foreigners at the minimum price of 500,000 Ringgit per unit, instead of 1,000,000 Ringgit per unit.Approval also permits 92 pct of the units in each tower of SKIES-Vantage Bay to be acquired by foreign interest.

ML Capital Group Inc announces expansion of SuperStar brand name with new product line of Hookah Pens

Wednesday, 16 Jul 2014 08:30am EDT

ML Capital Group Inc:Says it is launching new product line, SuperStar Hookah Pens, which are available for purchase online.Hookah pens have become more favorable alternative to smoking cigarettes and cigars and have given millions of people around the world a more enjoyable social experience.

Revive Therapeutics Ltd announces positive results of REV-001 Phase 2A proof-of-concept study

Friday, 27 Jun 2014 07:00am EDT

Revive Therapeutics Ltd:Positive results from second-half of its Phase 2a proof-of-concept study of REV-001 targeted for the treatment and/or prevention of opioid-induced respiratory depression for patients with sleep apnea in a post-operative setting.Purpose of Study is to determine effect of oral dose of REV-001 on alfentanil-induced respiratory depression and analgesia.Says results of the Study indicate that a single dose of REV-001 may treat and/or prevent opioid induced respiratory depression in a post-operative setting, without affecting analgesia.Says Treatments with REV-001 was safe and well tolerated at the 50 mg dose, was not associated with serious adverse events, and there was no treatment-related discontinuations.Says significant increase on respiratory drive as measured by inspired minute ventilation at an elevated expired PCO2 (VE55) of 36 pct (p = 0.039) by REV-001 as compared to placebo during high-dose alfentanil infusion induced respiratory depression.Treatments with REV-001 did not affect the opioids analgesic properties.Treatments with REV-001 did not affect sedation.

Canoe Mining Ventures Corp completes first drill program

Monday, 23 Jun 2014 10:30am EDT

Canoe Mining Ventures Corp:Completes first diamond drill program at its 100 pct owned Iron Lake Gold Project near White River, Ontario.

Venn Life Sciences Holdings PLC announces skin science patent grant

Thursday, 19 Jun 2014 02:00am EDT

Venn Life Sciences Holdings PLC:Says that its division has secured its first skin science patent for its anti-acne complex from the European Patent Office.The company has also commenced commercial discussions on Labskin, the breakthrough research grade human skin testing platform.

Revive Therapeutics submits Pre-IND package to the US FDA for Gout Drug Candidate, REV-002

Thursday, 5 Jun 2014 07:00am EDT

Revive Therapeutics Ltd:Submits a pre-Investigational New Drug (pre-IND) package to the U.S. Food and Drug Administration (FDA) for its gout drug candidate, REV-002.Submitted pre-IND package provides the FDA with information on Revive's REV-002, as well as a clinical trial plan for a proposed U.S. clinical trial.FDA's response to the pre-IND package will serve as a guide to Revive's preparation of a full IND application.

Revive Therapeutics Ltd announces positive pre-clinical results for Rett Syndrome

Wednesday, 14 May 2014 07:30am EDT

Revive Therapeutics Ltd:Says positive results from a pre-clinical study with tianeptine for the treatment of Rett syndrome, a rare disease (referred to by Revive as 'REV-003').

Revive Therapeutics Ltd submits pre-IND meeting request to US FDA

Wednesday, 30 Apr 2014 07:00am EDT

Revive Therapeutics Ltd:Submitted pre-Investigational New Drug meeting request to US FDA for its gout drug candidate REV-002.Requested an initial meeting with US FDA to review Revive's proposed clinical development plan required for approval of REV-002.

FinnAust Mining PLC announces new potential copper discovery at Hammaslahti Target

Tuesday, 29 Apr 2014 02:00am EDT

FinnAust Mining PLC:Report new area of copper mineralisation discovered as part of on-going exploration programme taking place around previously mined Hammaslahti copper, zinc and gold mine in southern Finland.Both zones contained within a large mineralised envelope of 20.45m at 1.12 pct copper.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: Thomson Reuters StreetEvents
$39.00
Provider: Thomson Reuters StreetEvents
$39.00
Provider: Thomson Reuters StreetEvents
$39.00
Provider: Raymond James Ltd. (Canada)
$100.00
Provider: Raymond James Ltd. (Canada)
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.